ORBi: Reinhart Konrad - Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study

Reference : Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment...


	Document type :	Scientific journals : Article
	Discipline(s) :	Human health sciences : Anesthesia & intensive care
	To cite this reference:	http://hdl.handle.net/2268/30945

Title :	Randomized, placebo-controlled trial of the anti-tumor necrosis factor antibody fragment afelimomab in hyperinflammatory response during severe sepsis: The RAMSES Study
Language :	English
Author, co-author :	Reinhart, Konrad [ > > ]
	Menges, Thilo [ > > ]
	Gardlund, Bengt [ > > ]
	Zwaveling, Jan Harm [ > > ]
	Smithes, Mark [ > > ]
	Vincent, Jean-Louis [ > > ]
	Tellado, Jose Maria [ > > ]
	Salgado-Remigio, Antonio [ > > ]
	Zimlichman, Reuven [ > > ]
	Withington, Stuart [ > > ]
	Tschaikowsky, Klaus [ > > ]
	Brase, Rainer [ > > ]
	Damas, Pierre [Université de Liège - ULg > > Soins intensifs >]
	Kupper, Hartmut [ > > ]
	Kempeni, Joachim [ > > ]
	Eiselstein, Juergen [ > > ]
	Kaul, Martin [ > > ]
Publication date :	2001
Journal title :	Critical Care Medicine
Publisher :	Lippincott Williams & Wilkins
Volume :	29
Issue/season :	4
Pages :	765-769
Audience :	International
ISSN :	0090-3493
e-ISSN :	1530-0293
City :	Philadelphia
Country :	PA
Keywords :	[en] sepsis ; interleukin-6 ; tumor necrosis factor ; monoclonal antibody ; cytokines ; infection ; critical illness ; clinical trial ; septic shock
Abstract :	[en] Objective: This study investigated whether treatment with the anti-tumor necrosis factor-a monoclonal antibody afelimomab would improve survival in septic patients with serum interleukin (IL)-6 concentrations of >1000 pg/mL. Design: Multicenter, double-blind, randomized, placebo-controlled study. Setting: Eighty-four intensive care units in academic medical centers in Europe and Israel. Patients: A total of 944 septic patients were screened and stratified by the results of a rapid qualitative immunostrip test for serum IL-6 concentrations. Patients with a positive test kit result indicating IL-6 concentrations of >1000 pg/mL were randomized to receive either afelimomab (n 5 224) or placebo (n 5 222). Patients with a negative IL-6 test (n 5 498) were not randomized and were followed up for 28 days. Interventions: Treatment consisted of 15-min infusions of 1 mg/kg afelimomab or matching placebo every 8 hrs for 3 days. Standard surgical and intensive care therapy was otherwise delivered. Measurements and Main Results: The study was terminated prematurely after an interim analysis estimated that the primary efficacy end points would not be met. The 28-day mortality rate in the nonrandomized patients (39.6%, 197 of 498) was significantly lower (p < .001) than that found in the randomized patients (55.8%, 249 of 446). The mortality rates in the IL-6 test kit positive patients randomized to afelimomab and placebo were similar, 54.0% (121 of 224) vs. 57.7% (128 of 222), respectively. Treatment with afelimomab was not associated with any particular adverse events. Conclusions: The IL-6 immunostrip test identified two distinct sepsis populations with significantly different mortality rates. A small (3.7%) absolute reduction in mortality rate was found in the afelimomab-treated patients. The treatment difference did not reach statistical significance.
Target :	Researchers ; Professionals
Permalink :	http://hdl.handle.net/2268/30945

File(s) associated to this reference

Fulltext file(s):

	File	Commentary	Version	Size	Access
Restricted access	61.pdf		Publisher postprint	90.01 kB	Request copy

All documents in ORBi are protected by a user license.

Dspace v1.5